Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Thermo Fisher Scientific Inc., consolidated balance sheet: assets (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021 Dec 31, 2020 Sep 26, 2020 Jun 27, 2020 Mar 28, 2020 Dec 31, 2019 Sep 28, 2019 Jun 29, 2019 Mar 30, 2019
Cash and cash equivalents 8,077 6,151 3,133 3,482 8,524 2,919 1,888 2,752 4,477 12,027 7,023 5,583 10,325 7,540 5,818 2,981 2,399 1,273 2,288 1,106
Accounts receivable, less allowances 8,221 8,370 8,019 7,922 8,115 7,671 7,745 7,889 7,977 5,557 5,476 5,554 5,741 5,186 4,478 4,508 4,349 4,384 4,129 4,155
Inventories 5,088 5,404 5,655 5,664 5,634 5,722 5,668 5,483 5,051 4,906 4,625 4,342 4,029 3,829 3,648 3,454 3,370 3,308 3,209 3,124
Contract assets, net 1,443 1,465 1,467 1,375 1,312 1,248 1,147 1,064 968 808 804 783 731 697 686 658 603
Other current assets 1,760 1,702 1,721 1,766 1,644 1,739 1,652 1,588 1,640 1,426 1,332 1,423 1,131 982 1,145 1,137 1,172 1,549 1,597 1,554
Current assets 24,589 23,092 19,995 20,209 25,229 19,299 18,100 18,776 20,113 24,724 19,260 17,685 21,957 18,234 15,775 12,738 11,893 10,514 11,223 9,939
Property, plant and equipment, net 9,448 9,167 9,292 9,354 9,280 8,628 8,529 8,448 8,333 7,049 6,560 6,133 5,912 5,180 4,887 4,736 4,749 4,420 4,394 4,192
Acquisition-related intangible assets, net 16,670 17,091 17,437 17,972 17,442 17,813 18,578 19,378 20,113 11,927 12,390 12,831 12,685 12,870 13,170 13,543 14,014 14,311 14,863 14,489
Other assets 3,999 4,124 4,108 3,983 4,007 4,308 4,306 4,424 4,640 2,991 2,584 2,459 2,457 1,995 2,061 2,057 2,011 1,860 1,733 1,740
Goodwill 44,020 43,583 43,273 43,140 41,196 40,488 41,066 41,721 41,924 26,909 26,904 26,823 26,041 25,782 25,700 25,614 25,714 25,624 25,757 25,236
Long-term assets 74,137 73,965 74,110 74,449 71,925 71,237 72,479 73,971 75,010 48,876 48,438 48,246 47,095 45,827 45,818 45,950 46,488 46,215 46,747 45,657
Total assets 98,726 97,057 94,105 94,658 97,154 90,536 90,579 92,747 95,123 73,600 67,698 65,931 69,052 64,061 61,593 58,688 58,381 56,729 57,970 55,596

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-28), 10-Q (reporting date: 2019-06-29), 10-Q (reporting date: 2019-03-30).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Thermo Fisher Scientific Inc. current assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Property, plant and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Thermo Fisher Scientific Inc. property, plant and equipment, net decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Thermo Fisher Scientific Inc. long-term assets decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Thermo Fisher Scientific Inc. total assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Thermo Fisher Scientific Inc. cash and cash equivalents increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Accounts receivable, less allowances Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Thermo Fisher Scientific Inc. accounts receivable, less allowances increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Thermo Fisher Scientific Inc. inventories decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.